TMED2: A Potential Cancer Drug Target and Biomarker (G10959)

Target Name: TMED2

NCBI ID: G10959

TMED2: A Potential Cancer Drug Target and Biomarker

TMED2 (Tissue Membrane Extender 2), also known as p24b1, is a protein that is expressed in various tissues throughout the body. It is a member of the tight junction family of transmembrane proteins, which are responsible for maintaining the integrity of the intercellular barrier . TMED2 is highly expressed in tissues that are susceptible to cancer, including the skin, breast, and prostate.

Recent studies have identified TMED2 as a potential drug target for various diseases, including cancer. TMED2 has been shown to be involved in several cellular processes that are crucial for cancer development, including cell signaling, angiogenesis, and immune evasion. Its expression has also been associated with the development of various types of cancer, including breast, prostate, and skin cancer.

One of the key mechanisms by which TMED2 contributes to cancer development is its role in cell signaling. TMED2 has been shown to be involved in several signaling pathways that are involved in cancer progression, including the PI3K/Akt signaling pathway. This pathway is involved in the regulation of cell survival and proliferation, and is a key target for many anti-cancer drugs.

In addition to its role in cell signaling, TMED2 has also been shown to be involved in the development of cancer in several other ways. For example, studies have shown that TMED2 can promote the formation of blood-brain barrier (BBB), a barrier that separates the brain from the bloodstream. The formation of the BBB is a critical barrier that helps to protect the brain from the development of cancer, but TMED2 has been shown to play a key role in its formation.

Another way in which TMED2 contributes to cancer development is its role in angiogenesis, the process by which new blood vessels are formed in the body. TMED2 has been shown to be involved in the regulation of angiogenesis, and its expression has been associated with the development of various types of cancer. For example, studies have shown that TMED2 can inhibit the formation of new blood vessels in the lungs, which is a critical step in the development of lung cancer.

In addition to its role in cancer development, TMED2 has also been shown to be involved in the regulation of immune responses. For example, studies have shown that TMED2 can modulate the activity of immune cells, including T cells and natural killer cells. This suggests that TMED2 may play a key role in the immune response, and may be a useful target for cancer immunotherapy.

TMED2 is also a potential biomarker for cancer diagnosis and monitoring. Its expression has been shown to be elevated in a variety of cancer types, including breast, prostate, and skin cancer. This suggests that TMED2 may be a useful biomarker for the diagnosis and monitoring of cancer.

In conclusion, TMED2 is a protein that is involved in several cellular processes that are crucial for cancer development. Its expression has been associated with the development of various types of cancer, including breast, prostate, and skin cancer. It has also been shown to play a key role in cell signaling, angiogenesis, and immune evasion. As a result, TMED2 is a potential drug target and biomarker for cancer. Further research is needed to fully understand the role of TMED2 in cancer development and to develop effective treatments.

Protein Name: Transmembrane P24 Trafficking Protein 2

Functions: Involved in vesicular protein trafficking. Mainly functions in the early secretory pathway but also in post-Golgi membranes. Thought to act as cargo receptor at the lumenal side for incorporation of secretory cargo molecules into transport vesicles and to be involved in vesicle coat formation at the cytoplasmic side. In COPII vesicle-mediated anterograde transport involved in the transport of GPI-anchored proteins and proposed to act together with TMED10 as their cargo receptor; the function specifically implies SEC24C and SEC24D of the COPII vesicle coat and lipid raft-like microdomains of the ER. Recognizes GPI anchors structural remodeled in the ER by PGAP1 and MPPE1. In COPI vesicle-mediated retrograde transport inhibits the GTPase-activating activity of ARFGAP1 towards ARF1 thus preventing immature uncoating and allowing cargo selection to take place. Involved in trafficking of G protein-coupled receptors (GPCRs). Regulates F2RL1, OPRM1 and P2RY4 exocytic trafficking from the Golgi to the plasma membrane thus contributing to receptor resensitization. Facilitates CASR maturation and stabilization in the early secretory pathway and increases CASR plasma membrane targeting. Proposed to be involved in organization of intracellular membranes such as the maintenance of the Golgi apparatus. May also play a role in the biosynthesis of secreted cargo such as eventual processing

More Common Targets